ホーム › 非小細胞肺癌 › アリゾナ州 › Phoenix
Phoenix、AZにおける非小細胞肺癌の臨床試験
Phoenixとその周辺地域（約30マイル以内）の拠点で、非小細胞肺癌に関する20件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
被験者募集中第1相
- Exelixis Clinical Site #67, Phoenix
A Platform Study in Non-Small Cell Lung Cancer (NSCLC)
被験者募集中第1/2相
- Research Site, Phoenix
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
被験者募集中第3相
- Ironwood Cancer & Research Centers, Phoenix
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
被験者募集中観察研究
- Mayo Clinic Hospital, Phoenix
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
被験者募集中第3相
- Mayo Clinic in Arizona - Phoenix ( Site 0147), Phoenix
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
被験者募集中第3相
- City of Hope, Phoenix, Phoenix
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
被験者募集中第3相
- Clinical Study Site, Phoenix
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
被験者募集中第3相
- Banner University Medical Center Phoenix, Phoenix
Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion
被験者募集中第1相
- Mayo Clinic, Phoenix
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
被験者募集中第1/2相
- Mayo Clinic Arizona, Phoenix
A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer
被験者募集中第1/2相
- Mayo Clinic Arizona, Phoenix
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
被験者募集中第3相
- Mayo Clinic Hospital in Arizona, Phoenix
A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations
被験者募集中第1/2相
- Mayo Clinic Hospital - Arizona, Phoenix
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
被験者募集中第1/2相
- USOR HonorHealth, Phoenix
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
被験者募集中第1相
- Mayo Clinic Hospital, Phoenix
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
被験者募集中第1相
- Mayo Clinic Hospital, Phoenix
Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
被験者募集中第3相
- Mayo Clinic Hospital in Arizona, Phoenix
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
被験者募集中第1相
- Mayo Clinic Comprehensive Cancer Center, Phoenix
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
被験者募集中観察研究
- Cancer Center at Saint Joseph's, Phoenix
Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform
被験者募集中観察研究
- Mayo Clinic in Arizona, Phoenix
他の都市における非小細胞肺癌の試験
- Houston, TX145件の研究
- New York City, NY120件の研究
- Arlington, VA104件の研究
- Nashville, TN97件の研究
- Boston, MA90件の研究
- Los Angeles, CA87件の研究
- St. Louis, MO73件の研究
- Chicago, IL61件の研究
- Baltimore, MD60件の研究
- San Antonio, TX59件の研究
- Columbus, OH56件の研究
- Washington, DC55件の研究
Phoenixにおける他の研究
- 乳がん25件の研究
- 大腸癌25件の研究
- 肥満症22件の研究
- 転移性癌20件の研究
- 心不全18件の研究
- 前立腺がん17件の研究
- がん（全種類）17件の研究
- 多発性骨髄腫16件の研究
- 膵臓がん16件の研究
- 心血管疾患16件の研究
- アルツハイマー病15件の研究
- 過体重15件の研究
ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。